HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

alanyl- tyrosyl- prolyl- glycyl- lysyl- phenylalanine

PAR - protease-activated receptor

Also Known As:

AYPGKF; Ala-Tyr-Pro-Gly-Lys-Phe; PAR4-activating peptide AYPGKF

Networked: 3 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Peptides: 82426
  - Oligopeptides: 519
    - alanyl-tyrosyl-prolyl-glycyl-lysyl-phenylalanine: 3

Experts

1.	Bauer, David: 1 article (08/2022)
2.	Brusilovskaya, Ksenia: 1 article (08/2022)
3.	Eichelberger, Beate: 1 article (08/2022)
4.	Gremmel, Thomas: 1 article (08/2022)
5.	Lee, Silvia: 1 article (08/2022)
6.	Mandorfer, Mattias: 1 article (08/2022)
7.	Panzer, Simon: 1 article (08/2022)
8.	Reiberger, Thomas: 1 article (08/2022)
9.	Schwabl, Philipp: 1 article (08/2022)
10.	Simbrunner, Benedikt: 1 article (08/2022)

Related Diseases

1.	Non-alcoholic Fatty Liver Disease 08/18/2022 - ": ACLD: advanced chronic liver disease; ADP: adenosine diphosphate; ALD: alcoholic liver disease; AYPGKF: PAR-4 agonist AYPGKF; CrP: collagen related protein; EPI: epinephrine; FACS: fluorescence-activated cell sorting; GP: glycoprotein; HVPG: hepatic venous pressure gradient; IQR: interquartile range; LPS: lipopolysaccharide; LSM: liver stiffness measurement; MFI: median fluorescence intensity; NAFLD: nonalcoholic fatty liver disease; PAM: lipopeptide Pam3CSK4; PAR: protease-activated receptor; PBS: phosphate-buffered saline; PH: portal hypertension; TIPS: transjugular intrahepatic portosystemic stent shunt; TLR: toll-like receptor; TRAP-6: thrombin receptor-activator peptide-6; vWF: von Willebrand factor."
2.	Thrombosis (Thrombus) 12/01/2008 - "PAR4 agonist (AYPGKF) treatment of the thrombus at 5 min enhanced aggregate stability during the shear step-up. "
3.	Alcoholic Liver Diseases (Alcoholic Liver Disease) 08/18/2022 - ": ACLD: advanced chronic liver disease; ADP: adenosine diphosphate; ALD: alcoholic liver disease; AYPGKF: PAR-4 agonist AYPGKF; CrP: collagen related protein; EPI: epinephrine; FACS: fluorescence-activated cell sorting; GP: glycoprotein; HVPG: hepatic venous pressure gradient; IQR: interquartile range; LPS: lipopolysaccharide; LSM: liver stiffness measurement; MFI: median fluorescence intensity; NAFLD: nonalcoholic fatty liver disease; PAM: lipopeptide Pam3CSK4; PAR: protease-activated receptor; PBS: phosphate-buffered saline; PH: portal hypertension; TIPS: transjugular intrahepatic portosystemic stent shunt; TLR: toll-like receptor; TRAP-6: thrombin receptor-activator peptide-6; vWF: von Willebrand factor."
4.	Liver Diseases (Liver Disease) 08/18/2022 - ": ACLD: advanced chronic liver disease; ADP: adenosine diphosphate; ALD: alcoholic liver disease; AYPGKF: PAR-4 agonist AYPGKF; CrP: collagen related protein; EPI: epinephrine; FACS: fluorescence-activated cell sorting; GP: glycoprotein; HVPG: hepatic venous pressure gradient; IQR: interquartile range; LPS: lipopolysaccharide; LSM: liver stiffness measurement; MFI: median fluorescence intensity; NAFLD: nonalcoholic fatty liver disease; PAM: lipopeptide Pam3CSK4; PAR: protease-activated receptor; PBS: phosphate-buffered saline; PH: portal hypertension; TIPS: transjugular intrahepatic portosystemic stent shunt; TLR: toll-like receptor; TRAP-6: thrombin receptor-activator peptide-6; vWF: von Willebrand factor."
5.	Hypertrophy 03/28/2003 - "AYPGKF, a modified PAR-4 agonist with increased potency at PAR-4, activates p38-mitogen-activated protein kinase but is a weak activator of phospholipase C, extracellular signal-regulated kinase, and cardiomyocyte hypertrophy; AYPGKF and thrombin, but not the PAR-1 agonist SFLLRN, activate Src. "

Related Drugs and Biologics

1.	Lipopeptides
2.	Toll-Like Receptors (Toll-Like Receptor)
3.	Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)
4.	Proteinase-Activated Receptors
5.	Thrombin Receptors (Thrombin Receptor)
6.	von Willebrand Factor
7.	Thrombin
8.	Proteins (Proteins, Gene)
9.	Protein Kinases (Protein Kinase)
10.	Type C Phospholipases

Related Therapies and Procedures

1.	Transjugular Intrahepatic Portasystemic Shunt
2.	Stents